Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Septerna, Inc. (SEPN : NSDQ)

• Company Description    Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 75

• Price / Volume Information    Yesterday's Closing Price: $27.88 Daily Weekly Monthly 20 Day Moving Average: 245,419 shares Shares Outstanding: 44.77 (millions) Market Capitalization: $1,248.30 (millions) Beta: 3.85 52 Week High: $30.50 52 Week Low: $4.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.57% 6.76% 12 Week 20.48% 18.54% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 250 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-338-3533 fax: - investors@septerna.com https://septerna.com

• General Corporate Information    Officers Jeffrey Finer - Chief Executive Officer; President and Director Jeffrey Tong - Chairman and Director Gil M. Labrucherie - Chief Financial Officer Abraham Bassan - Director Bernard Coulie - Director Peer Information Septerna, Inc. (CORR.) Septerna, Inc. (RSPI) Septerna, Inc. (CGXP) Septerna, Inc. (BGEN) Septerna, Inc. (GTBP) Septerna, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81734D104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/26/26 Share - Related Items Shares Outstanding: 44.77 Most Recent Split Date: (:1) Beta: 3.85 Market Capitalization: $1,248.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.20 Price/Cash Flow: - Price / Sales: 56.63 EPS Growth vs. Year Ago Period: 98.93% vs. Previous Quarter: 83.93% Sales Growth vs. Year Ago Period: 12,113.07% vs. Previous Quarter: 17,963.03% ROE 12/31/25 - - 09/30/25 - -17.98 06/30/25 - -31.52 ROA 12/31/25 - - 09/30/25 - -14.91 06/30/25 - -23.65 Current Ratio 12/31/25 - - 09/30/25 - 6.53 06/30/25 - 22.09 Quick Ratio 12/31/25 - - 09/30/25 - 6.53 06/30/25 - 22.09 Operating Margin 12/31/25 - - 09/30/25 - -323.47 06/30/25 - -12,053.03 Net Margin 12/31/25 - - 09/30/25 - -266.77 06/30/25 - -12,053.03 Pre-Tax Margin 12/31/25 - - 09/30/25 - -267.49 06/30/25 - -12,093.80 Book Value 12/31/25 - - 09/30/25 - 8.72 06/30/25 - 8.47 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©